Detalles de la búsqueda
1.
The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer.
BJU Int
; 133 Suppl 4: 27-36, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37904302
2.
How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
BJU Int
; 133 Suppl 3: 13-14, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37691457
3.
High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer.
BJU Int
; 130 Suppl 3: 5-7, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35362659
4.
A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies.
Eur Urol Open Sci
; 50: 91-105, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37101769
5.
A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
Eur Urol Open Sci
; 53: 90-97, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37441340
Resultados
1 -
5
de 5
1
Próxima >
>>